The PurpleLab^® Resource Center

PurpleLab®, a leading healthcare analytics company with one of the largest medical and pharmaceutical claims databases in the US, is pleased to announce its membership in the Network Advertising Initiative (NAI), the leading self-regulatory organization dedicated to responsible data collection and use in digital advertising. In joining the NAI, PurpleLab strengthens its commitment to maintaining…

Pharmaceutical advertisers and companies must develop marketing strategies that are multilayered as third-party cookies become a liability. Audience-based solutions remain part of this, but marketers should collaborate with their agency and ad tech partners to integrate real-world data in the pre-campaign planning, campaign launch and optimization phases. Discuss differences in content consumption based on health conditions, compare web behavior vs. TV viewing habits and how healthcare-focused supply analysis can feed into SPO applications.

More than a year has passed since Humira biosimilars were launched in the US, and with these, several other biosimilar drug approvals that either directly compete with Humira or are indicated for other rare immunologic conditions, macular degeneration, and oncology and hematological disease.  Ongoing industry surveillance of biosimilars and the   Source: “Biosimilars are becoming more widely available,…